Seeking Alpha

Affymax (AFFY +8.9%) wins backing from an FDA advisory panel for its peginesatide anemia drug,...

Affymax (AFFY +8.9%) wins backing from an FDA advisory panel for its peginesatide anemia drug, which competes with a rival drug from Amgen (AMGN). AFFY shares jumped 20%-plus on Monday when briefing documents related to today's meeting were released; trading has been halted since early this afternoon.
Comments (1)
  • InvestorProdigy
    , contributor
    Comments (8) | Send Message
     
    Classic Shakeout before the approval. Some hedge funds got stocks at very cheap prices.
    27 Mar 2012, 01:56 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|